Table 3 Multivariate p values to assess the differences in swelling and lymphatic pumping function at days 11, 13, and 18 in animals with etanercept administered by SOFUSAâ„¢ and the SC and ID routes and in untreated animals
From: Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis
| Â | ID | SC | Untreated |
|---|---|---|---|
Day 11 (overall, p = 0.62) | |||
 SOFUSA™ | 0.17 | 0.43 | 0.84 |
 ID |  | 0.70 | 0.35 |
 SC |  |  | 0.76 |
Day 13 (overall, p = 0.0002) | |||
 SOFUSA™ | 0.07 | 0.39 | <0.0001 |
 ID |  | 0.69 | 0.0017 |
 SC |  |  | 0.0015 |
Day 18 (overall, p <0.0001) | |||
 SOFUSA™ | 0.48 | 0.10 | <0.0001 |
 ID |  | 0.13 | 0.0006 |
 SC |  |  | 0.004 |